The incredible @ARosen380 on a @SusanGKomen panel on #AYACancers at #ASCO26 talking about the lack of survivorship planning for long-term survivors. “I had to create my own survivorship plan.” As patients like Allison and I live longer, we’re putting the wheels on the bus while the bus is on the road. This is even more challenging for patients like us who aren’t seen in AYA settings. It’s going to take us all - patients, PCPs, oncs, surgeons, etc - to solve this.

Nice slides about targated therapy options for EGFR Exon 20 insertion, HER2 mutated and ROS1 positive advanced NSCLC. Taken from the talk by @AnaVManana @ASCO #asco26

🎙️ @ASCO podcasts provide high quality cancer info & discussion in an accessible & enjoyable audio format! Give us a listen if you're not already a subscriber! Proud to be featured #ASCO26 w my fellow hosts Drs @DSoldatoMD @MikkaelSekeres @thenasheffect ascopubs.org/journal/op/podc…

Congrats @ChaewonHwangMD & team 👏 High-yield stage III NSCLC RWD: 🔹 Only ~54% received consolidation IO 🔹 IO linked to OS 42.1 vs 22.3 mo 🔹 Insurance, facility type & geography still shape outcomes PACIFIC-era benefit is clear but access remains the challenge. 🫁 #ASCO26 @ASCOTECAG @ASCO

#ASCO26 abst 1064 CAPTURE showed that in post-CDK4/6 PIK3CA-mutant HR+/HER2− MBC, alpelisib + fulvestrant did not beat capecitabine. PFS: 7.4 vs 9.4 months; ORR: 24% vs 50%. In patients with visceral disease, the picture was even more in favor of capecitabine. The presence of a biomarker alone does not define the right treatment sequence. Beating capecitabine is not that easy!!! I wonder how capivasertib + fulvestrant would have performed here?

And now, @FeliciaKnaul shares personal, patient-level, system-wide and even global experiences and challenges when facing cancer, in the context of adverse access, funding or gaps in technology. #ASCO26 @tomateloapecho And brings hope on how to close the cancer divide.

Outstanding initiative by @ASCO at #ASCO26. This is truly an international forum, and providing live translation shows respect for those have traversed the globe to attend. 🌎 The oncology world is getting smaller - truly an International Society of Clinical Oncology!

Love does not end at death. In oncology we do not save everyone. Our last encounter is the beginning of a long journey of grief for our patients’ loved ones. Thank you @ASCOPres for sharing your loss, Amy is now in all of our lives, her legacy inspires 40K+ at #ASCO26

Ngl, at parts I resisted this talk - realized my reflex to how do we keep the person in front of me alive - but everyone experiences loss. And we all need to know how to heal. Death is not a failure. The extra time you give people is meaningful. @IamDavidKessler #ASCO26

A remarkable doctor, scientist, mentor, and human being. If you were unable to attend the #ASCO26 Opening Ceremony, be sure to watch Dr. Eric Small’s (@ASCOPres) President’s Address online. It was centered on his values, his drive for translation and innovation, his global vision, and his personal experiences growing up in Mexico and losing his lifelong partner to cancer. We are fortunate to know you and to have such an inspirational leader at @UCSFCancer. @ASCO @EnriqueSoto8 @sueyom

@julio_frenk ahora en la sesión de apertura de #ASCO26 - el conocimiento como arma fundamental para la oncología global, en traducir/trasladar. Un orgullo e inspiración en la salud pública. @ASCOPres @ASCO

Powerful presidential address by Dr. Eric Small at #ASCO26. The charge could not be clearer. Discovery without translation is an incomplete promise. The science has to make it to the clinic, to the bedside, to our patients and in the ways that matter most to them. For every patient. Every cancer. Everywhere. @ASCOPres @UFHealthCancer

Today we presented our work #ASCO26 "Long-term toxicity perception and decision making with adjuvant immunotherapy in RCC: an exploratory HRQoL analysis from IMmotion010" 🧵 @oncodaily @OncoAlert @tompowles1

Good morning, Chicago! Thousands of oncologists and cancer researchers gathered with one focus: our patients. Excited for #ASCO26 to get underway!

There's nothing quite like the energy of #ASCO26. Excited to connect with researchers and clinicians from around the world, all working toward improving the lives of patients with cancer. #MoffittASCO26

Takeaways from @NCIDirector at #ASCO26 ➡️Recent pace of drug development has saved lives ➡️Cancer funding is stable ➡️Functional precision medicine - real-time human biology Science moves on, our patients deserve no less than continued progress against cancer 🫡

#ASCO26: Dr C Swanton NHS-Galleri trial. 142,000 patients randomized to annual MCED x 3 vs. standard care resulted in decreased stage IV and increased stage III cancer dx across multiple cancer types. Effect on cancer mortality not yet reported.

Good morning Chicago 🌞 Opening session #ASCO26: @CliffordHudis who emphasizes the collaboration between @NIH, our academic communities, pharmaceuticals for new drug development in cancer. We save lives, with each partner a crucial component to more people living after cancer 🙏